The biggest challenges currently facing companion diagnostic advancement

Expert Review of Molecular Diagnostics

Volumn 14, Issue 1, 2014, Pages 27-35

  Halim, Abdel Baset ^a  

^a DrugScan   (United States)

Author keywords

Companion diagnostics; Drug development; In vitro diagnostics; Molecular diagnostics; Oncology; Personalized medicine; Probability of success

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN E2; B RAF KINASE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; CD30 ANTIGEN; CETUXIMAB; CHEMOKINE RECEPTOR CCR5; CRIZOTINIB; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HLA B ANTIGEN; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 28B; K RAS PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PANITUMUMAB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTHROMBIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VEMURAFENIB;

ARTICLE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DIAGNOSTIC KIT; DRUG APPROVAL; DRUG INDUSTRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HLA SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MELANOMA; MOLECULAR DIAGNOSTICS; NEEDLE BIOPSY; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PROBABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; QUALITY IMPROVEMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84893051368     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.863150     Document Type: Article

References (21)

1. Pammolli F, Magazzini L, Riccaboni M The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438 (2011
2. Scannell JW, Blanckley A, Boldon AH, Warrington B Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200 (2012
3. Halim AB Biomarkers in drug development: A useful tool but discrepant results may have a major impact. In: Drug Discevery and Development-Present and Future Kapetanovic IM (Ed.). InTech Publishers, Croatia, 401-424 (2011
4. Chapman PB, Hauschild A, Robert AC et al Improved survival with Vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364, 2507-2516e(2011
5. Malone B Big changes coming to molecular DX reimbursement Clin. Lab. News 37(9), 1 (2011
6. Malone B Molecular diagnostics reimbursement in flux. Clin. Lab. News 39(1), 1 (2013
7. Stanek EJ, Sanders CL, Johansen-Taber KA et al. Adoption of pharmacogenomic testing by US physicians: Results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450-458 (2012
8. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380, 572-580 (2012
9. Harrison SC, Holmes MV, Humphries SE. Mendelian randomisation, lipids, and cardiovascular disease. Lancet 380, 543-545 (2012
10. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
11. Bedard PL, Hansen AR, Ratain MJ and Siu LL. Tumour heterogeneity in the clinic. Nature 501, 355-364 (2013
12. Bonini P, Plebani M, Ceriotti F and Rubboli F. Errors in laboratory medicine. Clin. Chem. 48(5), 691-698 (2002
13. Halim AB. Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: Evidence from proficiency testing results. Biomarkers Med. 3, 231-238 (2009
14. Halim AB. Discrepant results from laboratories impact patients receiving heparin or antithrombin therapy. Biomarkers Med. 5, 211-218 (2011
15. Halim AB. Proficiency testing for monitoring global laboratory performance and identifying discordance. Lab. Med. 44, e19-e30 (2013
16. Press MF, Hung G, Godolphin W and Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54, 2771-2777 (1994
17. Thomson TA, Hayes MM, Spinelli JJ et al. HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod. Pathol. 14, 1079-1086 (2001
18. Wolff AC, Elizabeth M, Hammond H et al. American society of clinical oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18-43 (2007
19. Hammond MEH, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010
20. Malone, B. The Pursuit of Traceability. Clin. Lab. News 35(10), 1 (2009
21. Robarge J D, Li L, Desta Z, Nguyen A, Flockhart DA. The star-Allele nomenclature: Retooling for translational genomics. Clin. Pharm. Ther. 82, 244-248 (2007